Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use

Journal of Clinical Pharmacology

Volumn 45, Issue 12, 2005, Pages 1345-1359

  Zhou, Limin ^a   Zuo, Zhong ^a,b   Chow, Moses Sing Sum ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Danshen; Danshensu; Salvia miltiorrhiza; Salvianolic acid B; Tanshinone IIA

Indexed keywords

3 (3,4 DIHYDROXYPHENYL)LACTIC ACID; 5,3' DIHYDROXY 7,4' DIMETHOXYFLAVANONE; ALPHA TOCOPHEROL; BAICALEIN; CRYPTOTANSHINONE; DAUCOSTEROL; DIAZEPAM; DITERPENE; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; MAGNESIUM LITHOSPERMATE; PROTOCATECHUALDEHYDE; PROTOCATECHUIC ACID; SALICYLIC ACID; SALVIA MILTIORRHIZA EXTRACT; SALVIANOLIC ACID B; SITOSTEROL; TANNIN; UNCLASSIFIED DRUG; URSOLIC ACID; WARFARIN;

ABDOMINAL DISCOMFORT; ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHINA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EUROPE; GASTROINTESTINAL TOXICITY; HEADACHE; HERB DRUG INTERACTION; HUMAN; HYPERLIPIDEMIA; JAPAN; REVIEW; SALVIA MILTIORRHIZA; TANSHINONE IIA; UNITED STATES; XEROSTOMIA;

ANGINA PECTORIS; ANIMALS; BENZOFURANS; CEREBROVASCULAR ACCIDENT; DRUGS, CHINESE HERBAL; FIBRINOLYTIC AGENTS; HERB-DRUG INTERACTIONS; HUMANS; HYPERLIPIDEMIAS; LACTATES; PHENANTHRENES; PHENANTHROLINES; RANDOMIZED CONTROLLED TRIALS;

EID: 27844511101     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005282630     Document Type: Review

References (98)

1. Ma JY. Clinical observation of the treatment of hyperlipemia with Danshen composite. Tianjin Zhongyi. 1998;15:24.
2. Wu XY, Guo XL. Clinical observation of the treatment of 60 hyperlipaemia with Fufang Danshen Dripping Pill. Hebei Zhongyi. 2000;22:671.
3. Ma WY, Yang JS, Gong CC, Liang L. Effect of Danshen composite on hyperlipaemia and blood rheology. Jiefangjun Yaoxue Xuebao. 2001;17:47-48.
4. Cui SK, Li GH. Clinical effect of Fufang Danshen Dripping Pill on hyperlipemia. Xiandai Zhongxiyi Jiehe Zazhi. 2003;11:1029-1030.
5. Mao JM, Gan ZQ. Clinical observation of Danshen composite on cerebral infarction. Jiefangjun Yaoxue Xuebao. 2001;17:49-50.
6. Guo ZX, Jia W, Gao WY, Xu ZH, Zhao LB, Xiao PG. Clinical investigation of composite Danshen Dripping Pill for the treatment of angina pectoris. Zhongguo Tianran Yaowu. 2003;1:124-128.
7. Liu XQ, Luo XT, Ouyang XA. Research advance of Fufang Danshen dosage forms. Shizhen Guoyi Guoyao. 2001;12:474-475.
8. Hu XR, Cao FM. An investigation of Danshen root: pharmacology study, clinical application and preparation. Zhongguo Xinyiyao. 2003;2:54-55.
9. Ge YR, Fang L, Li J. Review of research on pharmacopoeia prescription preparation of compound salvia. Zhong Cheng Yao. 2002;24:872-875.
10. Hu RF, Ma FY, Wang JH, Wang CY, Zhou A. Study on tanshinone rapid soluble tablet. Zhongguo Yaoshi. 2002;5:461-462.
11. Chu MQ, Gu HC, Liu GJ. Study on the preparation of tanshinone preliposomes by spray drying method. Zhongguo Yaoxue Zazhi. 2002;37:32-35.
12. Chu MQ, Liu S, Gu HC, Liu GJ. Study on solid dispersion of tanshinone. Huadong Ligong Daxue Xuebao. 2001;27:191-194.
13. The Pharmacopoeia Commission of PRC. Pharmacopoeia of the People's Republic of China Version 2005. Vol. 1. Beijing: Beijing Chemical Industry Press; 2005.
14. Tianjin Talisco Pharmaceutical Group Co. Ltd. Approval of Compound Danshen Dripping Pill (DSP) by FDA through pre-IND for clinical trials. Proceedings of Forum of Internationalized Chinese Materia Medica. 1998:18-30.
15. Kong DY. Chemical constituents of Salvia miltiorrhiza (Danshen). Zhongguo Yiyao Gongye Zazhi. 1989;20:279-285.
16. Zheng GH, Kakisawa H. Research on chemical constituents of Danshen. Zhongguo Yaoxue Zazhi. 1989;24:6-10.
17. Cai DG. Advances in the study of chemical constituents of Danshen. Zhongguo Zhongyao Zazhi. 1991;16:376-377.
18. Li LN. Water soluble active components of Salvia miltiorrhiza and related plants. Zhongguo Yaoxue. 1997;6:57-64.
19. Dong ZT, Jiang WD. Effect of danshensu on isolated swine coronary artery perfusion preparation. Yaoxue Xuebao. 1982;17:226-228.
20. Li CZ, Yang SC, Zhao FD, Yang YQ, Yang CX, Zhang DC. Anticoagulant studies of Danshen. Zhongxiyi Jiehe Zazhi. 1983;3:297-299.
21. Cheng ZH, Lou YP, Dai HJ, Xue F. Studies on effects of "danshensu" on experimental microcirculatory disturbances and plasma lactic acid concentrations. Shanghai Yike Daxue Xuebao. 1987;14:25-29.
22. Tang LH, Wang XM, Liang DQ. The protection of DS-182 during reperfusion of total ischemia heart. Zhongguo Bingli Shengli Zazhi. 1989;5:65-69.
23. Cao CM, Xia Q, Zhang X, Xu WH, Jiang HD, Chen JZ. Salvia miltiorrhiza attenuates the changes in contraction and intracellular calcium induced by anoxia and reoxygenation in rat cardiomyocytes. Life Sci. 2003;72:2451-2463.
24. Su XH, Liang DQ, Wang XM. The effect of danshensu (DS-182) of the injury of oxygen free radicals in myocardial mitochondria from rat myocardium. Zhongguo Bingli Shengli Zazhi. 1992;8:122-124.
25. Zhao BL, Jiang W, Zhao Y, Hou JW, Xin WJ. Scavenging effects of Salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem Mol Biol Int. 1996;38:1171-1182.
26. Chan K, Chui SH, Wong DY, Ha WY, Chan CL, Wong RN. Protective effects of danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction. Life Sci. 2004;75:3157-3171.
27. Chen YH, Du GH, Zhang JT. Salvianolic acid B protects brain against injuries caused by ischemia-reperfusion in rats. Zhongguo Xinyao Zazhi. 2000;21:463-466.
28. Li M, Zhao C, Wong RN, Goto S, Wang ZM, Liao FL. Inhibition of shear-induced platelet aggregation in rat by tetramethylpyrazine and salvianolic acid B. Clin Hemorheol Microcirc. 2004;31:97-103.
29. O K, Lynn EG, Vazhappilly R, Au-Yeung KK, Zhu DY, Siow YL. Magnesium tanshinoate B (MTB) inhibits low-density lipoprotein oxidation. Life Sci. 2001;68:903-912.
30. Wu YJ, Hong CY, Lin SJ, Wu P, Shiao MS. Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza. Arterioscl Thromb Vasc Biol. 1998;18:481-486.
31. O K, Cheung F, Sung FL, Zhu DY, Siow YL. Effect of magnesium tanshinoate B on the production of nitric oxide in endothelial cells. Mol Cell Biochem. 2000;207:35-39.
32. Ouyang XS, Takahashi K, Komatsu K, et al. Protective effects of Salvia miltiorrhiza on angiotensin II-induced hypertrophic responses in neonatal rat cardiac cells. Jpn J Pharmacol. 2001;87:289-296.
33. Au-Yeung KW, Zhu DY, O K, Siow YL. Inhibition of stress-activated protein kinase in the ischemic/reperfused heart: role of magnesium tanshinoate B in preventing apoptosis. Biochem Pharmacol. 2001;62:483-493.
34. Kang DG, Oh H, Sohn EJ, Hur TY, et al. Lithospermic acid B isolated from Salvia miltiorrhiza ameliorates ischemia/reperfusion-induced renal injury in rats. Life Sci. 2004;75:1801-1816.
35. Wu TW, Zeng LH, Fung KP, et al. Effect of sodium tanshinone IIA sulfonate in the rabbit myocardium and on human cardiomyocytes and vascular endothelial cells. Biochem Pharmacol. 1993;46:2327-2332.
36. Niu XL, Ichimori K, Yang X, et al. Tanshinone IIA inhibits low density lipoprotein oxidation in vitro. Free Radical Res. 2000;33:305-312.
37. Takahashi K, Ouyang XS, Komatsu K, et al. Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells. Biochem Pharmacol. 2002;64:745-750.
38. Zhuang YL, Chao RB. HPLC determination of danshensu and protocatechuic aldehyde in rat plasma. Yaoxue Xuebao. 1999;34:613-615.
39. Hong X, Mi SQ, Wang NS. Pharmacokinetics study of danshensu in compound Danshen Dripping Pill. Zhongyao Xinyao yu Linchuang Yaoli. 2000;11:286-288.
40. Pan GX, Zhang BL, Gao XM. Determination of danshensu in rat serum after oral administer compound Salvia Recipe. Zhongguo Zhongyao Zazhi. 2003;28:562-565.
41. Ye G, Wang CS, Li YY, Ren H, Guo DA. Simultaneous determination and pharmacokinetic studies on (3,4-dihydroxyphenyl)-lactic acid and protocatechuic aldehyde in rat serum after oral administration of Radix Salvia miltiorrhiza extract. J Chromatogr Sci. 2003;41:327-330.
42. He HB, Wang P, Chen Y, Qing ZL. Determination of danshensu and its pharmacokinetic parameter in rabbit by fluorometry. Shanghai Diyi Yixueyuan Xuebao. 1983;10:295-299.
43. Zhao FQ, Zheng NX, Sato H, Adachi I, Horikoshi I. Pharmacokinetics of a Chinese traditional medicine, danshensu (3,4-dihydroxyphenyllactic acid), in rabbits using high-performance liquid chromatography. Biol Pharm Bull. 1997;20:285-287.
44. Luo XJ, Bi KS, Zhou SY, Wei QH, Zhang RH. Determination of danshensu, a major active compound of Radix Salvia miltiorrhiza in dog plasma by HPLC with fluorescence detection. Biomed Chromatogr. 2001;15:493-496.
45. Zhao XF, Zhu ZM, Liu AF, Wang Z, Zheng XH. Qualitative and quantitative analysis of compound Danshen Dripping Pills by CS-HPLC. Zhong Cheng Yao. 2004;26:490-492.
46. Pei WJ, Zhao XF, Zhu ZM, Lin CZ, Zhao WM. Study of the determination and pharmacokinetics of compound Danshen Dripping Pill in human serum by column switching liquid chromatography electrospray ion trap mass spectrometry. J Chromotogr B. 2004;809: 237-242.
47. Liu Q, Chao RB. Determination of danshensu in urine and its pharmacokinetics in human. Yaoxue Xuebao. 2003;38:771-774.
48. Wang NS, Mi SQ, Hong X, Ou WP. LC/MS for the determination of relative ingredients of Radix Salvia Miltiorrhiza in biological sample after oral administration of Danshen Dripping Pill. Zhongyao Xinyao yu Linchuang Yaoli. 2000;11:141-142.
49. Zhang Y, Akao T, Nakamura N, et al. Extremely low bioavailability of magnesium lithospermate B, an active components from Salvia miltiorrhiza in rat. Planta Medica. 2004;70:138-142.
50. Zhang Y, Akao T, Nakamura N, et al. Magnesium lithospermate B is excreted rapidly into rat bile mostly as methylated metabolites, which are potent antioxidants. Drug Metab Dispos. 2004;32:752-757.
51. Li XC, Yu C, Sun WK, Liu GY, Jia JY, Wang YP. Pharmacokinetics of magnesium lithospermate B after intravenous administration in beagle dogs. Zhongguo Yaoli Xuebao. 2004;25:1402-1407.
52. Qiao JP, Hou PL, Li YW, Abliz Z. Determination of tanshinone IIA in rat plasma and the pharmacokinetics by RP-HPLC method. Yaoxue Xuebao. 2003;38:368-370.
53. Yuan Y, Jiang AH, Zhou J, Yang JY, Wang CQ. The absorption mechanism of tanshinone IIA in rat small intestine. Huaxi Yaoxue Zazhi. 2002;17:246-248.
54. Pang ZG, Wang BQ, Li YQ. Study on pharmacokinetics of tanshinone IIA in prescription. Xi'an Yike Daxue Xuebao. 1999;20: 457-459.
55. Xue M, Cui Y, Wang HQ, Luo YJ, Zhang B, Zhou ZT. Pharmacokinetics of cryptotanshinone and its metabolite in pigs. Yaoxue Xuebao. 1999;34:81-84.
56. Xie MZ, Shen ZF. Absorption, distribution, excretion and metabolism of cryptotanshinone. Yaoxue Xuebao. 1983;18:90-96.
57. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
58. Ding XM, Jia LZ, Wang CH. Curative effect of Danshen composite on stable angina pectoris. Zhongguo Linchuang Yixue. 1999;6:21-22.
59. He YZ. Treatment with Danshen composite of 40 patients with coronary heart disease and angina. Linchuang Shijian. 2004;22:107-108.
60. Wang XY, Qin L, Huang YF. Comparison of Danshen composite and isosorbide dinitrate in the treatment of angina pectoris and coronary heart disease. Jizhen Yixue. 1999;8:395-396.
61. Peng FQ. Clinical observation of Danshen composite in the treatment of coronary heart disease and angina. Xiandai Zhongxiyi Jiehe Zazhi. 2003;12:1377-1378.
62. Xu XM. Clinical effect of Danshen composite on 160 patients with angina pectoris. Zhongcaoyao. 2000;31:44.
63. Deng GH, He JT, Li BL. Clinical effect of Danshen composite on stable angina pectoris. Tianjin Yaoxue. 2002;14:48.
64. Wang X. Clinical effects observation of compound Danshen Dripping Pills in treating unsteady angina pectoris patients. Jiefangjun Yaoxue Xuebao. 2001;17:78-80.
65. Sun L, Dai PS, Shao J. Clinical effect of composite Danshen Dripping Pill on 40 patients with coronary heart disease and angina pectoris. Tianjin Zhongyi. 2000;17:6-7.
66. Xiang NZ, Li XY. A observation on the effect of Guttae S. miltiorrhiza to alleviate angina in patients with CHD. Zhongguo Linchuang Baojian Zazhi. 2004;7:110-111.
67. Wu K, Xia XM, Hui HS. A comparative study of drug resistance in the treatment of angina with Danshen composite and dinitrosorbide. The National Workshop on the Modernization of Traditional Chinese Medicine (Compound Danshen) '99. 1999:7.
68. Qian TL. Observation of the rapid pain relief on angina pectoris associated with coronary heart disease by composite Danshen Pills. Proceedings to '96 National Symposium on Composite Danshen Pharmaceuticals. 1996:36.
69. Wang YY, Wang H. Comparison of dissolving compound Salvia miltiorrhiza in mouth and dissolving nitroglycerin in mouth to treat angina pectoris. Henan Zhigong Yixueyuan Xuebao. 2004;16:227-229.
70. Sun D, Wang YZ. Clinical effect observation of composite Danshen Dripping Pill on coronary heart disease and angina. Qingdao Yiyao Weisheng. 2003;35:281-282.
71. Shen HQ, Wu RQ. Clinical effect comparison of composite Danshen Dripping Pill and Danshen tablet on coronary heart disease and angina pectoris. Shiyong Zhongxiyi Jihe Linchuang. 2003;3:7-8.
72. Jia LW, Du YY. Comparison of clinical effect of composite Danshen Dripping Pill with Fufang Danshen Tablet in patients with coronary heart disease and angina. Zhongguo Zhongyi Jizheng. 2000;9:106-107.
73. Zhou JZ, Xiong P. Clinical observation of composite Danshen dripping pill on 100 patients with coronary heart disease. Linchuang Yiyao Shijian Zazhi. 2003;12:264-265.
74. Zheng HB. The therapeutic effect of compound radices Salvia miltiorrhiza drop-Pilulae on angina of coronary heart disease: a randomized controlled clinical trial. Jibing Kongzhi Zazhi. 2000;4:284.
75. Lin P, Chen XA. Clinical effect comparison of composite Danshen Dripping Pill on angina pectoris. Guangzhou Yiyao. 2001;32:73.
76. Guan ZX, Zhang XQ. Curative effect of composite Salvia miltiorrhiza bunge complex aerosol on ischemic angina pectoris. Zhongguo Zhongxiyi Jiehe Jijiu Zazh. 2000;7:69-70.
77. Tan JQ, Li GQ, Li XJ. Clinical research of Fufang Danshen Aerosol on coronary heart disease and angina. Guangdong Yaoxue. 2000; 10:42.
78. Wang YY. Clinical observation of Salvia miltiorrhiza injection in treatment of coronary heart disease with angina pectoris. Zhongguo Zhongxiyi Jiehe Jijiu Zazhi. 2002;9:307-308.
79. Shao M. Clinical effect of Danshen Injection on unstable angina pectoris. Anhui Zhongyi Xueyuan Xuebao. 2003;22:13-15.
80. Jiang D. Clinical effect of Danshen Injection on coronary heart disease, angina and effect on platelet aggregation. Zhongguo Zhongyi Jizheng. 2003;12:105-106.
81. Shi YH. Control study of Fufang Danshen Dripping Pill and isosorbide dinitrite on stable angina pectoris. Zhongguo Zhongxiyi Jiehe Zazhi. 1997;17:23-25.
82. Wang ZQ, Zhou YT, Li XL. Evaluation of therapeutic effect of compound Danshen Dripping Pill on coronary heart disease using movement ECG. Helongjiang Yiyao Kexue. 2002;25:9.
83. Pan WY. Evaluation of exercise ECG of Fufang Danshen Dripping Pill and isosorbide dinitrite on stable angina pectoris and the metabolic effect on lipid. Shijie Yixue, Zazhi. 2002;6:55-57.
84. Li XL, Zhou YT, Huang HF. Evaluation of therapeutic effect of compound Danshen Dripping Pill on stable angina pectoris using movement ECG. Zhongguo Laonianxue Zazhi. 2003;23:183-184.
85. Wu B, Liu M, Zhang S. Danshen agents for acute ischemic stroke. Cochrane Database System Rev. 2004;4:CD004295.
86. Sze FK, Yeung FF, Wong E, Lau J. Does Danshen improve disability after acute ischemic stroke? Acta Neural Scand. 2005;111:118-125.
87. Zhang H, Yu C, Jia JY, et al. Contents of four active components in different commercial crude drugs and preparations of Danshen (Salvia miltiorrhiza). Zhongguo Xinyao Zazhi. 2002;23:1163-1168.
88. Shelelle PG, Morton SC, Suttorp MJ, Buscemi N, Friesen C. Challenges in systematic reviews of complementary and alternative medicine topics. Ann Intern Med. 2005;142:1042-1047.
89. Lo AC, Chan K, Yeung JH, Woo KS. The effects of Danshen (Salvia miltiorrhiza) on pharmacokinetics and pharmacodynamics of warfarin in rats. Eur J Drug Metab Pharmacokinet. 1992;17:257-262.
90. Chan K, Lo AC, Yeung JH, Woo KS. The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J Pharm Pharmacol. 1995;47:402-406.
91. Chan TY. Interaction between warfarin and Danshen (Salvia miltiorrhiza). Ann Pharmacother. 2001;35:501-504.
92. Tam LS, Chan TY, Leung WK, Critchley JA. Warfarin interactions with Chinese traditional medicines: Danshen and methyl salicylate medicated oil. Aust N Z J Med. 1995;25:258.
93. Yu CM, Chan JC, Sanderson JE. Chinese herbs and warfarin potentiation by 'Danshen.' J Intern Med. 1997;241:337-339.
94. Izzat MB, Yim AP, El-Zufari MH. A taste of Chinese medicine. Ann Thorac Surg. 1998;66:941-942.
95. Gupta D, Jalali M, Wells A, Dasgupta A. Drug-herb interactions: unexpected suppression of free Danshen concentrations by salicylate. J Clin Lab Anal 2002;16:290-294.
96. Deng H, Ma X, Xu R, et al. Mechanisms of protective actions of radix Salviae miltiorrhizae (RSM) against experimental hepatic injury in rats. Zhongguo Zhongyao Zazhi. 1992;17:233-236.
97. Qiao JP, Hou PL, Li YW, Abliz Z. Effects of the aqueous extract from Salvia miltiorrhiza Bge on the pharmacokinetics of diazepam and on liver microsomal cytochrome P450 enzyme activity in rats. J Pharm Pharmacol. 2003;55:1163-1167.
98. Ueng YF, Kuo YH, Wang SY, Lin YL, Chen CF. Induction of CYP1A by a diterpene quinone tanshinone IIA isolated from a medicinal herb Salvia miltiorrhiza in C57BL/6J but not in DBA/2J mice. Life Sci. 2004;74:885-896.